Emerging drugs for the treatment of vitiligo

References

• Judge MR, McLean WH, Munro CS. Acquired pigmentary disorders. In: Burns T, Breathnach S, Cox N, et al., editors. Rook’s textbook of dermatology. 9th ed. UK: Blackwell Publishing; 2010. p. 88.2242–2248.
   Google Scholar
• Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51:1206–1212.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cai Y, Shi M, et al. The prevalence of vitiligo: a meta-analysis. PloS One. 2016 Sep 27;11(9):e0163806.
   PubMedGoogle Scholar
• Silverberg NB. The epidemiology of vitiligo. Curr Dermatol Rep. 2015 Mar 1;4(1):36–43.
   Web of Science ®Google Scholar
• Shen C, Gao J, Sheng Y, et al. Genetic susceptibility to vitiligo: GWAS approaches for identifying vitiligo susceptibility genes and loci. Front Genet. 2016;7:3.
   PubMed Web of Science ®Google Scholar
• Mosenson JA, Zloza A, Nieland JD, et al. Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med. 2013;5(174):174ra28.
   PubMed Web of Science ®Google Scholar
• Mosenson JA, Eby JM, Hernandez C, et al. A central role for inducible heat-shock protein 70 in autoimmune vitiligo. Exp Dermatol. 2013;22(9):566–569.
   PubMed Web of Science ®Google Scholar
• Rashighi M, Agarwal P, Richmond JM, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014;6(223):223ra23.
   PubMed Web of Science ®Google Scholar
• Harris JE, Harris TH, Weninger W, et al. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin. J Invest Dermatol. 2012;132(7):1869–1876.
   PubMed Web of Science ®Google Scholar
• Schallreuter KU, Moore J, Wood JM, et al. In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Invest Dermatol Symp Proc. 1999;4(1):91–96.
   PubMedGoogle Scholar
• Shalbaf M, Gibbons NC, Wood JM, et al. Presence of epidermal allantoin further supports oxidative stress in vitiligo. Exp Dermatol. 2008 Sep;17(9):761–770.
   PubMed Web of Science ®Google Scholar
• Speeckaert R, van Geel N. Vitiligo: an update on pathophysiology and treatment options. Am J Clin Dermatol. 2017 Dec 1;18(6):733–744.
   PubMed Web of Science ®Google Scholar
• Felsten LM, Alikhan A, Petronic-Rosic V. Vitiligo: A comprehensive overview: part II: treatment options and approach to treatment. J Am Acad Dermatol. 2011 Sep 1;65(3):493–514.
   PubMed Web of Science ®Google Scholar
• Lotti T, Gori A, Zanieri F, et al. Vitiligo: new and emerging treatments. Dermatol Ther. 2008 Mar-Apr;21(2):110–117.
   PubMed Web of Science ®Google Scholar
• Grimes PE, Miller MM. Vitiligo: patient stories, self-esteem, and the psychological burden of disease. Int J Women Dermatol. 2018 Mar 1;4(1):32–37.
   PubMedGoogle Scholar
• Bae JM, Oh SH, Kang HY, et al. Development and validation of the vitiligo extent score for a target area (vesta) to assess the treatment response of a target lesion. Pigment Cell Melanoma Res. 2019 Mar;32(2):315–319.
   Google Scholar
• Taieb AV, Alomar A, Böhm M, et al. Guidelines for the management of vitiligo: the european dermatology forum consensus. Br J Dermatol. 2013 Jan;168(1):5–19.
   PubMed Web of Science ®Google Scholar
• Njoo MD, Spuls P, Bos JT, et al. Nonsurgical repigmentation therapies in vitiligo: meta-analysis of the literature. Arch Dermatol. 1998 Dec 1;134(12):1532–1540.
   PubMedGoogle Scholar
• Xing C, Xu A. The effect of combined calcipotriol and betamethasone dipropionate ointment in the treatment of vitiligo: an open, uncontrolled trial. J Drugs Dermatol. 2012 Oct;11(10):e52–4.
   PubMedGoogle Scholar
• Masuria BL, Batra A, Kothiwala RK, et al. Topical mometasone furoate for the treatment of childhood vitiligo. Indian J Dermatol Venereol Leprol. 1999 Sep 1;65(5):219.
   PubMedGoogle Scholar
• Westerhof W, Nieuweboer-Krobotova L, Mulder PG, et al. Left-right comparison study of the combination of fluticasone propionate and UV-A vs either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol. 1999 Sep 1;135(9):1061–1066.
   PubMedGoogle Scholar
• Wazir SM, Paracha MM, Khan SU. Efficacy and safety of topical mometasone furoate 0.01% vs. tacrolimus 0.03% and mometasone furoate 0.01% in vitiligo. J Pak Assoc Dermatol. 2016 Dec 21;20(2):89–92.
   Google Scholar
• Wong R, Lin AN. Efficacy of topical calcineurin inhibitors in vitiligo. Int J Dermatol. 2013 Apr;52(4):491–496.
   PubMed Web of Science ®Google Scholar
• Lubaki LJ, Ghanem G, Vereecken P, et al. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus. Arch Dermatol Res. 2010 Mar 1;302(2):131–137.
   PubMed Web of Science ®Google Scholar
• Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003 May 1;139(5):581–585.
   PubMedGoogle Scholar
• Fai D, Cassano N, Vena GA. Narrow‐band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients. J Eur Acad Dermatol Venereol. 2007 Aug;21(7):916–920.
   PubMed Web of Science ®Google Scholar
• Dawid M, Veensalu M, Grassberger M, et al. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double‐blind, vehicle‐controlled study. J Dtsch Dermatol Ges. 2006 Nov;4(11):942–946.
   PubMedGoogle Scholar
• Eryilmaz A, SeÓkin D, Baba M. Pimecrolimus: a new choice in the treatment of vitiligo? J Eur Acad Dermatol Venereol. 2009;23:1347–1348.
   PubMed Web of Science ®Google Scholar
• Boone B, Ongenae K, Van Geel N, et al. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol. 2007 Jan 1;17(1):55–61.
   PubMed Web of Science ®Google Scholar
• Şendur N, Karaman G, Saniç N, et al. Topical pimecrolimus: a new horizon for vitiligo treatment? J Dermatological Treat. 2006 Jan 1;17(6):338–342.
   PubMed Web of Science ®Google Scholar
• Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol. 2004 Sep 1;140(9):1065–1069.
   PubMedGoogle Scholar
• Nordal EJ, Guleng GE, Rönnevig JR. Treatment of vitiligo with narrowband‐UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right/left double‐blind comparative study. J Eur Acad Dermatol Venereol. 2011 Dec;25(12):1440–1443.
   PubMed Web of Science ®Google Scholar
• Chiaverini C, Passeron T, Ortonne JP. Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol. 2002 Mar;16(2):137–138.
   PubMed Web of Science ®Google Scholar
• Parsad D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology. 1998;197(2):167–170.
   PubMed Web of Science ®Google Scholar
• Khullar G, Kanwar AJ, Singh S, et al. Comparison of efficacy and safety profile of topical calcipotriol ointment in combination with NB‐UVB vs. NB‐UVB alone in the treatment of vitiligo: a 24‐week prospective right–left comparative clinical trial. J Eur Acad Dermatol Venereol. 2015 May;29(5):925–932.
   PubMed Web of Science ®Google Scholar
• Ada S, Şahin S, Boztepe G, et al. No additional effect of topical calcipotriol on narrow‐band UVB phototherapy in patients with generalized vitiligo. Photodermatol Photoimmunol Photomed. 2005 Apr;21(2):79–83.
   PubMed Web of Science ®Google Scholar
• Goktas EO, Aydin F, Senturk N, et al. Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo. J Eur Acad Dermatol Venereol. 2006 May;20(5):553–557.
   PubMed Web of Science ®Google Scholar
• Kapoor R, Phiske MM, Jerajani HR. Evaluation of safety and efficacy of topical prostaglandin E2 in treatment of vitiligo. Br J Dermatol. 2009 Apr;160(4):861–863.
   PubMed Web of Science ®Google Scholar
• Anbar TS, El‐Ammawi TS, Abdel‐Rahman AT, et al. The effect of latanoprost on vitiligo: a preliminary comparative study. Int J Dermatol. 2015 May;54(5):587–593.
   PubMed Web of Science ®Google Scholar
• Jha AK, Prasad S, Sinha R. Bimatoprost ophthalmic solution in facial vitiligo. J Cosmet Dermatol. 2018 Jun 1;17(3):437–440.
   PubMed Web of Science ®Google Scholar
• Grimes PE. Bimatoprost 0.03% solution for the treatment of nonfacial vitiligo. J Drugs Dermatol. 2016 Jun;15(6):703–710.
   PubMed Web of Science ®Google Scholar
• Colucci R, Lotti T, Moretti S. Vitiligo: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2012 Sep;13(13):1885–1899.
   PubMed Web of Science ®Google Scholar
• Schallreuter KU, Wood JM, Lemke KR, et al. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology. 1995;190(3):223–229.
   PubMed Web of Science ®Google Scholar
• Patel DC, Evans AV, Hawk JL. Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: an open, single‐centre study. Clin Exp Dermatol. 2002 Nov;27(8):641–644.
   PubMed Web of Science ®Google Scholar
• Yuksel EP, Aydin F, Senturk N, et al. Comparison of the efficacy of narrow band ultraviolet B and narrow band ultraviolet B plus topical catalase-superoxide dismutase treatment in vitiligo patients. Eur J Dermatol. 2009 Jul 1;19(4):341–344.
   PubMed Web of Science ®Google Scholar
• Schallreuter KU, Moore J, Behrens‐Williams S, et al. Rapid initiation of repigmentation in vitiligo with dead sea climatotherapy in combination with pseudocatalase (PC‐KUS). Int J Dermatol. 2002 Aug;41(8):482–7.129.
   PubMed Web of Science ®Google Scholar
• Shenoi SD, Prabhu S. Photochemotherapy (PUVA) in psoriasis and vitiligo. Indian J Dermatol Venereol Leprol. 2014 Nov 1;80(6):497.
   PubMed Web of Science ®Google Scholar
• Bae JM, Jung HM, Hong BY, et al. Phototherapy for vitiligo: a systematic review and meta-analysis. JAMA Dermatol. 2017 Jul 1;153(7):666–674.
   PubMed Web of Science ®Google Scholar
• Yones SS, Palmer RA, Garibaldinos TM, et al. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen–UV-A therapy vs narrowband–UV-B therapy. Arch Dermatol. 2007 May 1;143(5):578–584.
   PubMedGoogle Scholar
• Kanwar AJ, Dogra S. Narrow‐band UVB for the treatment of generalized vitiligo in children. Clin Exp Dermatol. 2005 Jul;30(4):332–336.
   PubMed Web of Science ®Google Scholar
• Hofer A, Kerl H, Wolf P. Long-term results in the treatment of vitiligo with oral khellin plus UVA. Eur J Dermatol. 2001 May 18;11(3):225–229.
   PubMed Web of Science ®Google Scholar
• Ortel B, Tanew A, Hönigsmann H. Treatment of vitiligo with khellin and ultraviolet A. J Am Acad Dermatol. 1988 Apr 1;18(4):693–701.
   PubMed Web of Science ®Google Scholar
• Procaccini EM, Riccio G, Monfrecola G. Ineffectiveness of topical khellin in photochemotherapy of vitiligo. J Dermatological Treat. 1995 Jan 1;6(2):117–120.
   Web of Science ®Google Scholar
• Siddiqui AH, Bhaggoe R, Hu R, et al. L-phenylalanine and UVA irradiation in the treatment of vitiligo. Dermatology. 1994;188(3):215–218.
   PubMed Web of Science ®Google Scholar
• Camacho F, Mazuecos J. Oral and topical L-phenylalanine, clobetasol propionate, and UVA/sunlight–a new study for the treatment of vitiligo. J Drugs Dermatol. 2002 Sep;1(2):127–131.
   PubMedGoogle Scholar
• Antoniou C, Schulpis H, Michas T, et al. Vitiligo therapy with oral and topical phenylalanine with UVA exposure. Int J Dermatol. 1989 Oct;28(8):545–547.
   PubMed Web of Science ®Google Scholar
• Fa Y, Lin Y, Chi XJ, et al. Treatment of vitiligo with 308‐nm excimer laser: our experience from a 2‐year follow‐up of 979 Chinese patients. J Eur Acad Dermatol Venereol. 2017 Feb;31(2):337–340.
   PubMed Web of Science ®Google Scholar
• Alhowaish AK, Dietrich N, Onder M, et al. Effectiveness of a 308-nm excimer laser in treatment of vitiligo: a review. Lasers Med Sci. 2013 May 1;28(3):1035–1041.
   PubMed Web of Science ®Google Scholar
• Wu CS, Hu SC, Lan CC, et al. Low‐energy helium‐neon laser therapy induces repigmentation and improves the abnormalities of cutaneous microcirculation in segmental‐type vitiligo lesions. Kaohsiung J Med Sci. 2008 Apr;24(4):180–189.
   PubMed Web of Science ®Google Scholar
• Kanwar AJ, Mahajan R, Parsad D. Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo. J Cutan Med Surg. 2013 Jul;17(4):259–268.
   PubMed Web of Science ®Google Scholar
• Majid I, Imran S. Relapse after methylprednisolone oral minipulse therapy in childhood vitiligo: a 12-month follow-up study. Indian J Dermatol. 2013 Mar;58(2):113.
   PubMedGoogle Scholar
• Radmanesh M, Saedi K. The efficacy of combined PUVA and low‐dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatological Treat. 2006 Jan 1;17(3):151–153.
   PubMed Web of Science ®Google Scholar
• Madarkar M, Ankad BS, Manjula R. Comparative study of safety and efficacy of oral betamethasone pulse therapy and azathioprine in vitiligo. Clin Dermatol Rev. 2019 Jul 1;3(2):121.
   Google Scholar
• Behl PN. Treatment of vitiligo with homologous thin Thiersch’s skin grafts. Curr Med Pract. 1964;8:218–221.
   Google Scholar
• Majid I, Imran S. Ultrathin split-thickness skin grafting followed by narrowband UVB therapy for stable vitiligo: an effective and cosmetically satisfying treatment option. Indian J Dermatol Venereol Leprol. 2012 Mar 1;78(2):159.
   PubMed Web of Science ®Google Scholar
• Khandpur S, Sharma VK, Yashpal M. Comparison of minipunch grafting versus split‐skin grafting in chronic stable vitiligo. Dermatol Surg. 2005 Apr;31(4):436–441.
   PubMed Web of Science ®Google Scholar
• Malakar S, Dhar S. Treatment of stable and recalcitrant vitiligo by autologous miniature punch grafting: a prospective study of 1,000 patients. Dermatology. 1999;198(2):133–139.
   PubMed Web of Science ®Google Scholar
• Li J, WW FU, ZHENG ZZ, et al. Suction blister epidermal grafting using a modified suction method in the treatment of stable vitiligo: a retrospective study. Dermatol Surg. 2011 Jul;37(7):999–1006.
   PubMed Web of Science ®Google Scholar
• Suraj B, Mrityunjay Kumar S, Anil Kumar S. Comparative evaluation of punch grafting, suction blister and split thickness in treatment of stable vitiligo: a prospective study. Int J Contem Med Res. 2017;4(4):801–804.
   Google Scholar
• Mulekar SV. Long-term follow-up study of segmental and focal vitiligo treated by autologous, noncultured melanocyte-keratinocyte cell transplantation. Arch Dermatol. 2004 Oct 1;140(10):1211–1215.
   PubMedGoogle Scholar
• Chen YF, Yang PY, Hu DN, et al. Treatment of vitiligo by transplantation of cultured pure melanocyte suspension: analysis of 120 cases. J Am Acad Dermatol. 2004 Jul 1;51(1):68–74.
   PubMed Web of Science ®Google Scholar
• Noncultured extracted hair follicle outer root sheath cell suspension for transplantation in vitiligo.
   Google Scholar
• Donaparthi N, Chopra A. Comparative study of efficacy of epidermal melanocyte transfer versus hair follicular melanocyte transfer in stable vitiligo. Indian J Dermatol. 2016 Nov;61(6):640.
   PubMed Web of Science ®Google Scholar
• Singh M, Kotnis A, Jadeja SD, et al. Cytokines: the yin and yang of vitiligo pathogenesis. Expert Rev Clin Immunol. 2019 Feb 1;15(2):177–188.
   PubMed Web of Science ®Google Scholar
• Lv M, Li Z, Liu J, et al. 155 inhibits the proliferation of CD8+ T cells via upregulating regulatory T cells in vitiligo. Mol Med Rep. 2019 Oct 1;20(4):3617–3624.
   PubMed Web of Science ®Google Scholar
• Arora AK, Kumaran MS. Pathogenesis of vitiligo: an update. Pigment Int. 2017;4:65–77.
   Google Scholar
• Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36.
   PubMed Web of Science ®Google Scholar
• Chen X, Guo W, Chang Y, et al. 792 oxidative stress-induced IL-15 trans-presentation in keratinocytes contributes to CD8+ T cells activation via JAK-STAT pathway in vitiligo. J Invest Dermatol. 2019;139:S137.
   Web of Science ®Google Scholar
• Agarwal P, Rashighi M, Essien KI, et al. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. J Invest Dermatol. 2015;135(4):1080–1088.
   PubMed Web of Science ®Google Scholar
• Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2017;19. DOI:10.1007/s40257-017-0336-3.
   Web of Science ®Google Scholar
• Speeckaert R, van Geel N. Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo. Exp Dermatol. 2017 Jul;26(7):630–634.
   PubMed Web of Science ®Google Scholar
• Singh A, Kanwar AJ, Parsad D, et al. Randomized controlled study to evaluate the effectiveness of dexamethasone oral minipulse therapy versus oral minocycline in patients with active vitiligo vulgaris. Indian J Dermatol Venereol Leprol. 2014 Jan 1;80(1):29.
   PubMed Web of Science ®Google Scholar
• Singh H, Kumaran M,S, Bains A, et al. A randomized comparative study of oral corticosteroid minipulse and low-dose oral methotrexate in the treatment of unstable vitiligo. Dermatology. 2015;231:286–290.
   PubMed Web of Science ®Google Scholar
• Taneja A, Kumari A, Vyas K, et al. Cyclosporine in treatment of progressive vitiligo: an open-label, single-arm interventional study. Indian J Dermatol Venereol Leprol. 2019;85:528–531.
   PubMed Web of Science ®Google Scholar
• Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol. 2015;151(10):1110–1112.
   PubMed Web of Science ®Google Scholar
• Liu LY, Strassner JP, Refat MA, et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017;77(4):675–682.
   PubMed Web of Science ®Google Scholar
• Gianfaldoni S, Tchernev G, Wollina U, et al. Micro-focused phototherapy associated to Janus kinase inhibitor: a promising valid therapeutic option for patients with localized vitiligo. Open Access Maced J Med Sci. 2018;6(1):46–48.
   PubMedGoogle Scholar
• McKesey J, Pandya AG. A pilot study of 2% tofacitinib cream with narrow-band UVB for the treatment of facial vitiligo. J Am Acad Dermatol. 2019 Aug;81(2):646–648. DOI:10.1016/j.jaad.2019.04.032
   Web of Science ®Google Scholar
• US Food and Drug Administration. Xeljanz prescribing information. [cited 2018 Nov 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203214s018bl.pdf
   Google Scholar
• Harris JE. Vitiligo and alopecia areata: apples and oranges? Exp Dermatol. 2013;22(12):785–789.
   PubMed Web of Science ®Google Scholar
• Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol. 2017;76(6):1054–1060.e1.
   PubMed Web of Science ®Google Scholar
• Joshipura D, Alomran A, Zancanaro P, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B. J Am Acad Dermatol. 2018;78(6):1205–1207.
   PubMed Web of Science ®Google Scholar
• Noel M, Gagne C, Bergeron J, et al. Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo. Lipids Health Dis. 2004;3:7.
   PubMedGoogle Scholar
• Vanderweil SG, Amano S, Ko WC, et al. A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo. J Am Acad Dermatol. 2017;76(1):150–151.e3.
   PubMed Web of Science ®Google Scholar
• Centre Hospitalier Universitaire de Nice. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); Atorvastatin in Active Vitiligo. [cited 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT02432534 NLM Identifier: NCT02432534.
   Google Scholar
• Niezgoda A, Winnicki A, Kosmalski T, et al. The evaluation of vitiligous lesions repigmentation after the administration of atorvastatin calcium salt and simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial. Trials. 2019 [cited 2019 Jan 25];20(1):78.
   PubMedGoogle Scholar
• Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151(1):42–50.
   PubMed Web of Science ®Google Scholar
• Lotti T, Buggiani G, Troiano M, et al. Targeted and combination treatments for vitiligo comparative evaluation of different current modalities in 458 subjects. Dermatol Ther. 2008 Jul;21:S20–6.
   PubMed Web of Science ®Google Scholar
• Babino G, Giunta A, Esposito M, et al. UVA1 laser in the treatment of vitiligo. Photomed Laser Surg. 2016 May 1;34(5):200–204.
   PubMed Web of Science ®Google Scholar
• Lotti T, Tchernev G, Wollina U, et al. Successful treatment with UVA 1 laser of non-responder vitiligo patients. Open Access Maced J Med Sci. 2018 Jan 25; 6(1):43.
   PubMedGoogle Scholar
• Lotti T, Wollina U, Tchernev G, et al. An Innovative therapeutic protocol for vitiligo: experience with the use of fraxel herbium laser, topical latanoprost and successive irradiation with UVA-1 laser. Open Access Maced J Med Sci. 2018;6(1):49.
   PubMedGoogle Scholar
• Zhang Y, Lin H, Guo X, et al. A case series pilot study on the combination of 5-aminolevulinic acid and photodynamic therapy (ALA-PDT) for treatment of vitiligo. An Bras Dermatol. 2018 Aug;93(4):539–545.
   PubMed Web of Science ®Google Scholar
• Bae JM, Lee JH, Jung YS, et al. The efficacy of a gain-switched 311-nm Titanium: sapphire laser in the treatment of vitiligo: a pilot study of 14 patients. JAMA Dermatol. 2017 Oct 1;153(10):1055–1056.
   PubMed Web of Science ®Google Scholar
• Bae JM, Eun SH, Lee HN, et al. Comparison of 311‐nm Titanium: sapphire laser and 308‐nm excimer laser treatment for vitiligo: A randomized controlled non‐inferiority trial. Lasers Surg Med. 2019 Mar;51(3):239–244.
   PubMed Web of Science ®Google Scholar
• Abdallah M, Lotfi R, Othman W, et al. Assessment of tissue FoxP3+, CD4+ and CD8+ T-cells in active and stable nonsegmental vitiligo. Int J Dermatol. 2014;53:940–946.
   PubMed Web of Science ®Google Scholar
• Parsad D, Pandhi R, Juneja A. Effectiveness of oral ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol. 2003 May;28(3):285–287.
   PubMed Web of Science ®Google Scholar
• Dell’Anna ML, Mastrofrancesco A, Sala R, et al. Antioxidants and narrow band‐UVB in the treatment of vitiligo: a double‐blind placebo controlled trial. Clin Exp Dermatol. 2007;32:631–636.
   PubMed Web of Science ®Google Scholar
• Middelkamp‐Hup MA, Bos JD, Riuz‐Diaz F, et al. Treatment of vitiligo vulgaris with narrow band UVB and oral polypodium leucotomos extract: a randomized double‐blind placebo controlled study. J Eur Acad Dermatol Venereol. 2007;21:942–950.
   PubMed Web of Science ®Google Scholar
• Abdelmaksoud A, Dave DD, Lotti T, et al. Topical methotrexate 1% gel for treatment of vitiligo: A case report and review of the literature. Dermatol Ther. 2019 Jul;2:e13013.
   Google Scholar
• Handjani F, Aghaei S, Moezzi I, et al. Topical mycophenolate mofetil in the treatment of vitiligo: a pilot study. Dermatol Pract Concept. 2017 Apr;7(2):31.
   PubMedGoogle Scholar
• Ramaiah A, Kar HK, Garg VK, et al. A double blind randomized phase IV clinical trial of basic fibroblast. Growth Factor Related Deca-peptide in Vitiligo.  Pigm Dis. 2015.
   Google Scholar
• Subhashini PK, Sankar K, Kambar C, et al. Comparative study of efficacy and safety of topical active fragment of basic fibroblast growth factor (B FGF) 0.1% solution V/S betamethasone valerate 0.1% ointment in the treatment of vitiligo patients.J Dental and Med Sci. 2015;14(6):41–47.
   Google Scholar
• Ruiz‐Argüelles A, García‐Carrasco M, Jimenez‐Brito G, et al. Treatment of vitiligo with a chimeric monoclonal antibody to CD 20: a pilot study. Clin Exp Immunol. 2013 Nov;174(2):229–236.
   PubMed Web of Science ®Google Scholar
• Korobko IV, Lomonosov KM. Acridone acetic acid, sodium salt, as an agent to stop vitiligo progression: a pilot study. Dermatol Ther. 2014 Jul;27(4):219–222.
   PubMed Web of Science ®Google Scholar
• Lotti T, Hercogova J, Fabrizi G. Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy. Expert Opin Pharmacother. 2015 Nov 2; 16(16):2485–2496.
   PubMed Web of Science ®Google Scholar
• Brigham and Women’s Hospital. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); Open-label Pilot Study of Abatacept for the Treatment of Vitiligo; [ cited 2016 Jun 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02281058 NLM Identifier: NCT02281058.
   Google Scholar
• Genexin.com [Internet]. [ cited 2016 Jun 30]. Available from: http://www.genexine.com/m31.php.
   Google Scholar
• Al-Shobaili HA. Update on the genetics characterization of vitiligo. Int J Health Sci (Qassim). 2011 Jul;5(2):167.
   PubMedGoogle Scholar
• [cited 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT01419964. NLM identifier: NCT01419964.
   Google Scholar
• [cited 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT03468855. NLM identifier: NCT03468855.
   Google Scholar
• [cited 2019]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT04103060. NLM identifier: NCT04103060.
   Google Scholar
• Swope VB, Abdel-Malek Z, Kassem LM, et al. Interleukins 1a and 6 and tumor necrosis factor a are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol. 1991;96:180–185.
   PubMed Web of Science ®Google Scholar
• Alghamdi KM, Khurrum H, Taieb A, et al. Treatment of generalized vitiligo with anti-TNF-a agents. J Drugs Dermatol. 2012;11:534–539.
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Gregoriou S, Larios G, et al. Etanercept in the treatment of vitiligo. Dermatology. 2007;215:84–85.
   PubMed Web of Science ®Google Scholar
• Mery-Bossard L, Chaby G, Maccari F, et al. New onset vitiligo under biologic agents: a case series. Ann Rheum Dis. 2014;73:S2.
   Web of Science ®Google Scholar
• Speeckaert R, Mylle S, van Geel N. IL-17A is not a treatment target in progressive vitiligo. Pigm Cell Mel Res. 2019. DOI:10.1111/pcmr.12789
   Web of Science ®Google Scholar